Conclusions Despite recent advances in obesity pharmacotherapies, the need for improvements in medication efficacy, whilst minimising adverse effects, remains
IGF-1 LR3 functions through direct, sustained agonism of the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, activating the same downstream intracellular signalling cascades as native IGF-1 but with substantially reduced IGFBP-mediated attenuation and a far longer biological activity window
Pharmacokinetic DDIs of GLP-1 RAs and a Dual GLP-1/GIP RA Drug-Metabolizing Enzyme-and Transporter-Mediated DDIs GLP-1 RAs and a dual GLP-1/GIP RA are now approved for the treatment of type 2 diabetes and obesity, with patients frequently managing coexisting metabolic diseases that require additional medications
There are possible side effects, and its not meant for everyone, so please talk to your doctor and do your research about Semaglutide
The FDA warned in 2019 against using supplement powder for IV mixing because of contamination dangers
Injectable hair protocol: Dose: 1-2mg daily Frequency: Daily or 5 days weekly Duration: 16-24 weeks minimum (longer than anti-aging protocols) Cycle: 8 weeks on, 4 weeks off, repeat Topical scalp protocol: Concentration: 0.5% solution Application: 1-2ml to thinning areas twice daily Duration: 6+ months for meaningful assessment Technique: Apply to clean, dry scalp